This content was published on Oct 24, 2024 On Thursday, the Swiss Federal Railways presented its first fully renovated InterCity tilting train (ICN). Read more: Swiss railways presents first fully ...

Vyalev, also known as Produodopa, has been approved in 35 countries, with more than 4200 patients having started treatment.

AbbVie should report strong Q3 2024 results next week and increase the full-year guidance. Explore more details here.

The U.S. Food and Drug Administration has approved AbbVie's Vyalev (foscarbidopa and foslevodopa) for adults living with ...

Neurologist Jason Aldred helped conduct trials for the device in Spokane through his work at Selkirk Neurology, where he ...

The U.S. Food and Drug Administration has approved Vyalev (foscarbidopa and foslevodopa) for adults living with advanced ...

Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with ...

The U.S. FDA has approved the first 24-hour continuous subcutaneous infusion for adults with advanced Parkinson’s disease.

North Chicago, Illinois Saturday, October 19, 2024, 12:00 Hrs [IST] ...

The FDA has just approved a new injectable treatment for adults with advanced Parkinson’s disease called Vyalev (also known as Produodopa).

The first levodopa-based treatment for motor fluctuations in people with advanced Parkinson's disease, VYALEVa subcutaneous ...